Title
The role of NIIMBL to advance manufacturing for Cell and Gene Therapy treatments
Conference Dates
February 6 – 10, 2022
Abstract
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.
Funding of $70 million has been committed by NIST for the next 5 years of NIIMBL and this is expected to be more than matched by participants. A key focus will be advancing manufacturing of Gene Therapy and Cell Therapy based products. Discussion is invited regarding the best role for this public-private partnership.
Recommended Citation
Barry Buckland, "The role of NIIMBL to advance manufacturing for Cell and Gene Therapy treatments" in "Advancing Manufacture of Cell and Gene Therapies VII", Sharon Brownlow, Cell & Gene Therapy Catapult, UK; Sean Palecek, University of Wisconsin, USA; Damian Marshall, Achilles Therapeutics, UK; Fernanda Masri, Cell & Gene Therapy Catapult, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/cellgenetherapies_vii/36